Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation
therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with
ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA)
persistence after radical prostatectomy(RP).
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School